Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2/3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
[Translation] JC002 tablets postprandial comparative pharmacokinetic clinical trial
主要目的:比较健康成年参与者餐后单次口服JC002、右布洛芬片和右旋布洛芬口服混悬液后,三种制剂餐后药代动力学的相似性及右布洛芬在人体内的暴露差异。
次要目的:研究受试制剂JC002和对照制剂右布洛芬片、右旋布洛芬口服混悬液在健康成人参与者中的安全性(包括不良事件、严重不良事件、生命体征、体格检查、实验室检查、12导联心电图等检查)。
[Translation] Primary objective: To compare the similarity of postprandial pharmacokinetics and the differences in dextro ibuprofen exposure in healthy adult participants after a single oral dose of JC002, dextro ibuprofen tablets, and dextro ibuprofen oral suspension.
Secondary objective: To investigate the safety (including adverse events, serious adverse events, vital signs, physical examination, laboratory tests, 12-lead electrocardiogram, etc.) of the investigational formulation JC002 and the control formulations dextro ibuprofen tablets and dextro ibuprofen oral suspension in healthy adult participants.
JC005在中国健康男性受试者中安全性、耐受性和初步有效性临床研究
[Translation] Clinical study of the safety, tolerability, and preliminary efficacy of JC005 in healthy male subjects in China.
观察不同剂量JC005对健康男性受试者的安全性,探索JC005最大耐受剂量(MTD),为Ⅱ期临床试验剂量提供依据。
初步评估JC005的人体有效性。
[Translation] To observe the safety of different doses of JC005 in healthy male subjects and explore the maximum tolerated dose (MTD) of JC005, providing a basis for the dosage in Phase II clinical trials.
To preliminarily assess the human efficacy of JC005.
[Translation] A pilot study on the comparative pharmacokinetics of JC002 tablets after meals
主要目的:比较健康成年受试者在进餐后单次口服JC002和右布洛芬片的药代动力学参数,评价两种制剂药代动力学受餐食影响的程度。
次要目的:研究受试制剂JC002和对照制剂右布洛芬片在健康成人受试者中的安全性(包括不良事件、严重不良事件、生命体征、体格检查、实验室检查、12导联心电图等检查)。
[Translation] Primary objective: To compare the pharmacokinetic parameters of JC002 and dexibuprofen tablets after a single oral administration in healthy adult subjects, and to evaluate the extent to which the pharmacokinetics of the two preparations are affected by meals.
Secondary objective: To study the safety of the test preparation JC002 and the control preparation dexibuprofen tablets in healthy adult subjects (including adverse events, serious adverse events, vital signs, physical examination, laboratory tests, 12-lead electrocardiogram, etc.).
100 Clinical Results associated with Beijing Jiacheng Biomedical Technology Development Co., Ltd
0 Patents (Medical) associated with Beijing Jiacheng Biomedical Technology Development Co., Ltd
100 Deals associated with Beijing Jiacheng Biomedical Technology Development Co., Ltd
100 Translational Medicine associated with Beijing Jiacheng Biomedical Technology Development Co., Ltd